Approved periprocedural dosing recommendations for TPO-RAs in patients with CLD
| Platelet count . | Dosing . | Timing . |
|---|---|---|
| Avatrombopag | ||
| 40-50 × 109/L | 40 mg daily for 5 d, then stop | Start 10-13 d prior to procedure |
| <40 × 109/L | 60 mg daily for 5 d, then stop | Start 10-13 d prior to procedure |
| Lusutrombopag | ||
| <50 × 109/L | 3 mg daily for 7 d, then stop | Start 8-14 d prior to procedure |
| Platelet count . | Dosing . | Timing . |
|---|---|---|
| Avatrombopag | ||
| 40-50 × 109/L | 40 mg daily for 5 d, then stop | Start 10-13 d prior to procedure |
| <40 × 109/L | 60 mg daily for 5 d, then stop | Start 10-13 d prior to procedure |
| Lusutrombopag | ||
| <50 × 109/L | 3 mg daily for 7 d, then stop | Start 8-14 d prior to procedure |